Major Shareholding Notification • Jan 31, 2019
Major Shareholding Notification
Open in ViewerOpens in native device viewer
Regulated information
Brussels, Belgium, 31 January 2019, 5.45 pm (CET) – ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 28 January, 2019, the result of which is - following a capital increase completed on January 10th – that SA SRIW and SA SOFIPOLE have jointly now 4,94% of the Company's voting rights, and have thus decreased its stake below the 5% threshold.
The statement dated 28 January 2019 notably includes the following information:
Passive crossing of a threshold
• Notification by
A parent company or a person in control
• Person subject to the notification requirement
SRIW SA – Avenue Maurice Destenay 13, 4000 Liège SOFIPOLE SA – Avenue Maurice Destenay 13, 4000 Liège
• Date of the transaction
January 10th , 2019
• Threshold crossed (%)
Downward crossing of the 5% threshold
• Denominator
A total of 18,640,535 voting rights
• This notification is available on ASIT biotech's website, in the Documentation / Regulated information section:
https://www.asitbiotech.com/investors/documentation
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
Company Philippe Ghem ASIT biotech Tel.: +32 2 264 03 90 [email protected]
Media and Investor Relations - France NewCap Dusan Oresansky / Pierre Laurent Tel.: +33 1 44 71 94 92 [email protected]
Tel.: +32 2 290 90 93 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.